Are biologic treatments widely available in the UK? 

Biologic treatments, also known as biological therapies, are widely available in the UK and have transformed the management of inflammatory conditions like Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA). While these drugs are more expensive than traditional treatments, they are accessible to patients who meet specific clinical criteria set by the National Institute for Health and Care Excellence (NICE). In recent years, the availability of these treatments has expanded significantly, partly due to the introduction of “biosimilars”—more cost-effective versions of original biologic drugs that allow the NHS to offer these therapies to more people than ever before. 

What We’ll Discuss in This Article 

• The eligibility criteria for biologics on the NHS 

• The transition from conventional DMARDs to biological therapy 

• The role of biosimilars in expanding patient access 

• Specific biologics available for RA and PsA in the UK 

• How the “Treat-to-Target” strategy influences biologic use 

• The process of starting a biologic: Screening and monitoring 

Biologic treatments are a standard part of the NHS treatment pathway for inflammatory arthritis. However, they are generally not used as a first-line treatment. Most patients must first try at least two conventional disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate or sulfasalazine, without seeing sufficient improvement before they become eligible for a biologic. The NHS notes that biological treatments are usually only used if conventional DMARDs have not been effective on their own or are not suitable for the patient. 

Eligibility and the NHS Pathway 

To ensure that biologics are used where they provide the most benefit, the NHS follows strict NICE guidelines. For a patient to be approved for a biologic, a consultant rheumatologist must provide evidence that the condition is “active” enough to justify the treatment. 

Rheumatoid Arthritis: 

Clinicians use the DAS28 (Disease Activity Score), which looks at 28 specific joints. In 2021, NICE expanded access so that patients with “moderate” disease activity (a DAS28 score between 3.2 and 5.1) could access biologics, whereas previously only those with “severe” disease were eligible. 

Psoriatic Arthritis: 

Eligibility often requires evidence of at least three tender and three swollen joints after failing at least two conventional DMARDs. 

This stepped approach ensures that patients who do not respond to simpler, less expensive medications can move quickly to more powerful therapies. 

The Impact of Biosimilars 

The wide availability of biologics in the UK has been greatly supported by the introduction of biosimilar medicines. A biosimilar is a biological medicine that is highly similar to another biologic already licensed for use (the “reference” medicine). 

Because biosimilars are less expensive to produce, they save the NHS hundreds of millions of pounds each year. These savings are reinvested into the healthcare system, allowing the NHS to treat tens of thousands of additional patients earlier in their disease course. NHS England supports the use of biosimilars, stating they are safe, effective, and interchangeable with the original products when prescribed by a clinical team. 

Common Biologics Available in the UK 

There are several classes of biologics available on the NHS, each targeting a different part of the immune system. 

Biologic Class	Common Examples	Target
TNF Inhibitors	Adalimumab, Etanercept, Infliximab	Blocks a protein called TNF-alpha
IL-17 Inhibitors	Secukinumab, Ixekizumab	Targets IL-17 (Common in PsA)
B-Cell Inhibitors	Rituximab	Targets B-cells in the blood
IL-6 Inhibitors	Tocilizumab, Sarilumab	Blocks the IL-6 inflammatory pathway
T-Cell Modulators	Abatacept	Prevents T-cells from activating

In addition to these, a newer class of “targeted synthetic” drugs called JAK inhibitors (like Tofacitinib and Upadacitinib) are also widely available and work in a similar way to biologics but are taken as a daily tablet. 

Starting Treatment: The “Biologic Review” 

Once you are approved for a biologic, you will undergo a series of pre-treatment checks. This includes blood tests to screen for “latent” infections like Tuberculosis (TB) and Hepatitis, as well as a chest X-ray. 

Most biologics are self-administered via an injection pen at home, though some require an infusion (drip) in a hospital day unit. You will typically be reviewed by your rheumatology team after 12 to 16 weeks to see if the treatment is working. If it is effective, you will stay on the medication long-term; if not, your consultant may switch you to a different biologic with a different “mode of action.” 

Conclusion 

Biologic treatments are widely available and accessible across the UK for those who need them. By following national clinical guidelines and utilizing cost-effective biosimilars, the NHS ensures that patients with moderate to severe inflammatory arthritis can access life-changing therapy. If you feel your current treatment is not controlling your symptoms, you should discuss your eligibility for a biologic with your rheumatologist. If you experience a severe allergic reaction after an injection, such as difficulty breathing or swelling of the face, call 999 immediately. 

Authority Snapshot (E-E-A-T Block) 

This evidence-based guide follows UK clinical standards for the use of biological therapies, drawing from the NHS, NICE, and the British Society for Rheumatology. The content is authored by the Medical Content Team and reviewed by Dr. Rebecca Fernandez, a UK-trained physician with experience in internal medicine and emergency care. Our aim is to provide safe, factual, and practical information to help the public navigate complex autoimmune treatment pathways.